8.50
+0.01(+0.12%)
Currency In USD
Address
440 Armand-Frappier Boulevard
Laval, QC H7V 4B4
Canada
Phone
14507810115
Sector
Healthcare
Industry
Biotechnology
Employees
251
First IPO Date
December 18, 2009
| Name | Title | Pay | Year Born |
| Mr. Bruce Pritchard BA, CA, FIOD | Chief Executive Officer | 698,944 | 1974 |
| Dr. Gary J. Bridger Ph.D. | Interim Chief Scientific Officer & Non-Independent Director | 264,690 | 1963 |
| Ms. Marie Iskra L.L.B. | Corporation Sec. & Gen. Counsel | 435,822 | 1977 |
| Mr. Patrick Sartore | Pres | 613,823 | 1975 |
| Dr. Christopher L. Penney | Chief Scientific Officer of Therapeutics - ProMetic BioSciences Inc | 0 | N/A |
| Dr. Robert G. Rohwer | Member of Scientific Advisory Committee - PRDT | 0 | N/A |
| Ms. N. Nicole Rusaw C.A., CPA | Chief Financial Officer | 0 | 1974 |
| Dr. John Bienenstock CM, FRCP, FRPC, FRSC, M.D.(Hon) | Member of Advisory Committee - Therapeutics | 0 | 1937 |
| Ms. N. Nicole Rusaw C.A., C.P.A. | Chief Financial Officer | 0 | 1974 |
| Ms. N. Nicole Rusaw C.A., C.P.A., CA, CPA, HBACC | Chief Financial Officer | 0 | 1973 |
| Shrinal Inamdar | Mang. of Investor Relations & Communications | 0 | N/A |
| Dr. Steven J. Burton | Pres of Prometic Bioseparations Ltd | 0 | N/A |
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the treatment of idiopathic pulmonary, liver, cardiac, or skin fibrosis with fezagepras or related derivatives and respiratory diseases. It is also developing antagonist candidate programs, including G-protein coupled receptor 84 and Oxo-eicosanoid receptor 1, which are in preclinical stage. The company was formerly known as Prometic Life Sciences Inc. and changed its name to Liminal BioSciences Inc. in October 2019. Liminal BioSciences Inc. was incorporated in 1994 and is headquartered in Laval, Canada.